首页> 外文期刊>Circulation. Arrhythmia and electrophysiology >Use of high-volume haemodiafiltration in patients with refractory septic shock and acute kidney injury
【24h】

Use of high-volume haemodiafiltration in patients with refractory septic shock and acute kidney injury

机译:大容量血液透析滤过在难治性脓毒性休克和急性肾损伤患者中的应用

获取原文
获取原文并翻译 | 示例
           

摘要

Background. High-volume haemofiltration (HVHF) has been used successfully in animal models with sepsis, and preliminary data have shown that this technique may improve the haemody-namics in patients with refractory septic shock. We used high-volume continuous venovenous haemodiafiltration (CVVHDF) in patients with acute kidney injury (AKI) and refractory septic shock to evaluate their outcome when compared with their prognosis predicted by scores of severity. Methods. This is a cohort study in a Medical and Surgical Intensive Care Unit. Fifty-five patients with refractory septic shock and AKI were included in the study. Results. High-volume CVVHDF was started in patients with AKI and septic shock requiring norepi-nephrine dose >0.2 ug/kg/min. AKI was classified according to the RIFLE criteria. Treatment was implemented within the first 24 h of refractory septic shock with a dialysis dose of 70 mL/kg/h until reversal of shock or death. Fifty-five patients were treated with high-volume CVVHDF with an observed mortality of 63%, similar to the mortality predicted by the APACHE II and SAPS II scores. Conclusion. Survival rate in our patients with AKI and refractory septic shock treated with high-volume CVVHDF was identical to survival predicted by the severity scores. Treatment with high-volume haemodiafiltraton is applicable to severely ill patients with septic shock but does not confer any clear advantage in terms of survival. This therapy should not be implemented on a routine basis in patients with AKI and refractory septic shock.
机译:背景。大容量血液滤过(HVHF)已成功用于脓毒症动物模型,初步数据表明该技术可改善难治性败血性休克患者的血液动力学。与严重程度评分预测的预后相比,我们对急性肾损伤(AKI)和顽固性败血性休克患者使用了大容量连续静脉血液透析滤过(CVVHDF)评估其结局。方法。这是医学和外科重症监护室的一项队列研究。该研究纳入了55名顽固性败血性休克和AKI患者。结果。 AKI和败血性休克患者需要大剂量CVVHDF,败血症性休克需要去甲肾上腺素剂量> 0.2 ug / kg / min。根据RIFLE标准对AKI进行了分类。在顽固性败血性休克的前24小时内进行治疗,透析剂量为70 mL / kg / h,直至休克或死亡逆转。 55名患者接受了大剂量CVVHDF治疗,观察到的死亡率为63%,与APACHE II和SAPS II评分所预测的死亡率相似。结论。用大容量CVVHDF治疗的AKI和难治性败血性休克患者的生存率与严重程度评分所预测的生存率相同。大剂量血液透析滤过治疗适用于患有脓毒性休克的重症患者,但在生存率方面无明显优势。对于AKI和难治性败血性休克患者,不应常规使用这种疗法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号